TRACON Pharmaceuticals, Inc. Common Stock
TCON
TCON was delisted on the 27th of June, 2024.
33 hedge funds and large institutions have $45.1M invested in TRACON Pharmaceuticals, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 14 increasing their positions, 10 reducing their positions, and 4 closing their positions.
51% more capital invested
Capital invested by funds: $29.8M → $45.1M (+$15.3M)
40% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 10
0% more funds holding
Funds holding: 33 → 33 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$3.29M |
| 2 |
PCM
Puissance Capital Management
New York
|
+$3.29M |
| 3 |
TI
Telemetry Investments
New York
|
+$1.2M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.06M |
| 5 |
Renaissance Technologies
New York
|
+$554K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$184K |
| 2 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$178K |
| 3 |
Russell Investments Group
London,
United Kingdom
|
-$105K |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$86K |
| 5 |
VF
Virtu Financial
New York
|
-$61.2K |
TCON Hedge Fund Activity: Q2 2018 in Review
33 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in TRACON Pharmaceuticals, Inc. Common Stock (TCON) for Q2 2018, worth a combined $45.1M — up 51% from $29.8M a quarter earlier.
Fund positioning in TCON was balanced in Q2 2018: 4 funds opened new positions, 4 closed out, 14 added to existing stakes and 10 trimmed.
The largest buyer was 683 Capital Management, adding an estimated $3.29M. The largest seller was Jacobs Levy Equity Management, cutting an estimated $184K.
- 33 institutional investors held TRACON Pharmaceuticals, Inc. Common Stock (TCON) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $45.1M of TRACON Pharmaceuticals, Inc. Common Stock stock for Q2 2018, up 51% quarter-over-quarter.
- 4 funds opened new TRACON Pharmaceuticals, Inc. Common Stock positions in Q2 2018 and 4 closed out, a net change of 0 holders.
- The largest TRACON Pharmaceuticals, Inc. Common Stock buyer in Q2 2018 was 683 Capital Management, an estimated $3.29M added.
- The largest TRACON Pharmaceuticals, Inc. Common Stock seller in Q2 2018 was Jacobs Levy Equity Management, an estimated $184K sold.
Based on aggregated 13F filings for Q2 2018.